CD68 and cancer: In addition, compared to patients with cancer not treated with ICI therapy, the inflammatory composition of coronary plaque in patients treated with ICIs has been shown to favor a lymphocyte‐predominant phenotype with an increased CD3/CD68 ratio, which may lead to plaque progression and instability [10].